Reviva Pharmaceuticals Holdings, Inc. RVPH

Healthcare Biotechnology

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system and respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

NDAQ:RVPH - Post by User

Reviva Pharmaceuticals Holdings, Inc. > RVPH update.....

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Apr 26, 2021 11:31am

114 Views

Post# 33066675

RVPH update.....

Just broke the "Strike 2" RBL...........I'm at a quandry where Strike 3 is....this isn't trading like alot of the previous runners I've seen.

I will stick with support at $6.00 and make a call then.

GL

<< Previous

Bullboard Posts

Next >>

A potential breakthrough in spinal cord and optic nerve injury treatment